APLMW (Apollomics) Buildings And Improvements : $0.00 Mil (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Apollomics Buildings And Improvements?

Apollomics's quarterly buildings and improvements increased from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($2.57 Mil) but then declined from Dec. 2023 ($2.57 Mil) to Jun. 2024 ($0.00 Mil).

Apollomics's annual buildings and improvements increased from Dec. 2021 ($2.37 Mil) to Dec. 2022 ($2.87 Mil) but then declined from Dec. 2022 ($2.87 Mil) to Dec. 2023 ($2.57 Mil).

Apollomics Buildings And Improvements Historical Data

The historical data trend for Apollomics's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Buildings And Improvements Chart

Apollomics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

2.32

2.37

2.87

2.57

Apollomics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Buildings And Improvements	Get a 7-Day Free Trial			-	2.87	-	2.57	-

Apollomics Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Apollomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

APLM:USA

Address

989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404

Website

https://www.apollomicsinc.com

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.